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Introduction: Stereotactic body radiation therapy (SBRT) is enter-
ing routine clinical use for selected patients with early-stage non-
small cell lung cancer. Post-SBRT radiological changes are com-
monly seen on follow-up computed tomography (CT) imaging and
can cause diagnostic dilemmas. The aim of this study is to describe
the incidence, radiological severity, and long-term morphology of
these changes.
Methods: CT scans from patients treated between 2003 and June
2008 were eligible for evaluation if radiological follow-up had been
performed at our center for at least 2 years, and there was no definite
evidence of local recurrence. Timing, incidence, morphology, and
severity of lung changes were determined.
Results: CT scans from 61 patients (68 lesions) with a median
follow-up of 2.5 years were evaluated. Within 6 months, 54% of
lesions were associated with additional radiological abnormalities,
and this figure reached 99% after 36 months. Most changes were
scored as mild to moderate, and although the median time to first
observation was 17 weeks, 25% appeared 1 year post-SBRT. In
47% of lesions, the morphology or severity of changes continued to
evolve more than 2 years posttreatment.
Conclusions: Mild-moderate radiological changes are common af-
ter lung SBRT. Some degree of late change is nearly universal, and
it often continues to evolve more than 2 years post-SBRT. Clinicians
should be aware of these radiological findings, which need to be
distinguished from the uncommon cases of local failure post-SBRT.
Key Words: Lung cancer, Radiation fibrosis, Radiation pneumoni-
tis, Radiation therapy, Stereotactic.
(J Thorac Oncol. 2011;6: 1221–1228)
Stereotactic body radiation therapy (SBRT) is a form ofhigh-precision radiation therapy that is frequently deliv-
ered in 3 to 8 fractions over 1 to 3 weeks. There is increasing
evidence to support its use in selected patients with early-
stage non-small cell lung cancer (NSCLC). Prospective mul-
ticenter studies have shown that it can achieve local control
rates in excess of 88%,1,2 and a meta-analysis of published
studies shows that improved local control rates and survival
are achieved with SBRT, when compared with convention-
ally fractionated radiotherapy delivered in 5 to 7 weeks.3
Population-based analyses have revealed that the percentage
of elderly patients with stage I NSCLC who underwent
radiotherapy increased after the introduction of SBRT, with a
corresponding improvement in their survival.4 SBRT out-
comes have also been evaluated in patients with stage I
NSCLC who have declined surgery,5 and the body of avail-
able evidence has been considered strong enough to support
phase III trials comparing surgery versus SBRT for first-line
treatment of operable patients.6
Computed tomography (CT) is the primary imaging
modality for evaluating response and for detecting changes in
pulmonary tissues after lung SBRT (Table 1). We previously
reported that acute radiological changes develop in approxi-
mately 60% of patients.8 The late fibrotic process after
high-dose radiation can be dynamic and continue for many
years,9,15,17 which at times makes it difficult to distinguish
post-SBRT changes from tumor recurrence.9,18–20 For this
reason, we have aimed to better characterize the incidence
and morphology of late radiological lung changes after SBRT
by evaluating post-SBRT CT studies in patients with a
minimum of 2 years radiological follow-up.
PATIENTS AND METHODS
Patients and Treatment
The SBRT program at VU University medical center
commenced in 2003 and has included evaluations of survival,
local control, toxicity, and quality of life. Patients were
eligible for this retrospective study if they fulfilled the fol-
lowing criteria: (i) lung SBRT treatment for a stage I NSCLC
between 2003 and June 2008, (ii) regular radiological fol-
low-up performed for at least 2 years at our center (rather
than their referring center), and (iii) no definite radiological
evidence of local recurrence on the study CT scans.
Patient selection, 4D-imaging protocols, use of a risk-
adapted fractionation schemes, and the treatment techniques
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TABLE 1. A Summary of Studies Reporting Radiological Changes After Stereotactic Lung Radiotherapy
Study Patients
Follow-Up (FU) Duration and Intended
Imaging Frequency
Lung Changes After Stereotactic
Body Radiotherapy (SBRT) Comments
Takeda et al.7 128 (133 lesions) All patients minimum 6 mo FU or radiation
pneumonitis (RP) grade 1 and
minimum 5 mo FU after imaging RP.
Median FU 12 mo (5–45). CT at 1 and 3
mo post-SBRT, 3 monthly years 1–2 and
then 4–6 monthly
Grades 0, 1, 2, and 3 RP in 27%,
52%, 16%, and 5%. In all
patients with grade 2 or 3 RP
symptoms developed at the
same time as, or after,
radiological changes
Palma et al.8 75 Eligible patients all had CT within 4 mo
post-SBRT
57% of patients had CT changes,
mainly diffuse or patchy
consolidation
Evaluated early clinical and
radiological toxicity post-
SBRT. PTV had to be 100
ml; 5% had symptomatic
pneumonitis (one patient had
grade 3). No correlation
between severity of clinical
pneumonitis and radiological
changes
Guckenberger
et al.9
70 (86 lesions) Median FU 16 mo (1.5–85), CT at 6 and 12
wk post-SBRT and then 3 monthly
No reaction in 76% of patient at 6
wk, at 3 mo spotted-streaky
condensation in 32%, at 6 mo
this was 34% with 33% dense
consolidation, retraction
appeared at 9 mo (22%) and at
12 mo dense consolidation
(41%) and retraction (36%)
dominate
At 12 mo could not differentiate
residual tumor from lung
changes in 33%. Fibrotic
remodeling for years in selected
patients. Symptomatic
pneumonitis in 10% of patients
(median time to diagnosis 5 mo
1.5–9)
Trovo et al.10 68 (70 lesions) FU 3 monthly year 1, 4 monthly year 2,
and 6 monthly years 3 and 4. CT scans
divided into 4 groups: (i) 6 wk post-
SBRT (n  68), (ii) 2–6 mo post-SBRT
(n  33), (iii) 7–12 mo (n  35), and
(iv) 13–18 mo (n  25)
No reaction in 54% patients at 6
wk, patchy consolidation, and
ground-glass opacity (GGO)
(33%) or diffuse consolidation
(27%) developed 2–6 mo post-
SBRT. Between 7 and 12 mo,
54% modified conventional
fibrosis and 20% mass like.
Between 13 and 18 mo, these
were 44% and 28%,
respectively
4% grade 2 pulmonary toxicity.
No radiographic correlation
with PTV, location, dose or
dose-volume parameters
Kyas et al.11 64 Median FU 10.2 mo (2.3–46.2). Computed
tomography (CT) at 5–7 wk post-SBRT
and then 3–4 monthly
83% demonstrated the defined
endpoint of CT-detected new,
hyperdense, “perifocal” tissue
reaction at a median of 4.6 mo
post-SBRT (1.5–16.8)
Dmean, V7 and V10 equally able
to predict risk of toxic lung
events. Found increased
radiosensitivity of lower part of
lung. No clinical pneumonitis
requiring treatment
Baumann
et al.12
57 Median FU 23 mo (3–42). X-rays or CT at
6 wk post-SBRT and then at 3, 6, 9, 12,
18, 24, and 36 mo
Fibrosis in 38% 7% grade 3 dyspnea, 4% grade 3
fibrosis. Trend to more fibrosis
in T2 vs. T1 tumors (not
statistically significant)
Kimura
et al.13
45 (52 lesion) Eligible patients minimum 6 mo FU,
median FU 18 mo (6–56). CT at 1, 3,
and 6 mo post-SBRT and then 6 monthly
Acute findings within 6 mo: no
increase in density 33%, diffuse
consolidation 39%, and patchy
consolidation and GGO in 15%.
Late findings: modified
conventional fibrosis 62%, mass
like 17%, scar like 21%
80% of lesions showing acute
diffuse consolidation evolved to
modified conventional fibrosis,
59% with no acute increase in
density evolved to scar-like
fibrosis
Mirri et al.14 40 (42 lesions) Minimum 4 mo FU, median 19 (4–46) 90% of patients had CT changes
in irradiated lung within 2–6
mo (median 4)
Symptomatic clinical lung toxicity
in 10%
Matsuo
et al.15
37 (40 lesions) Required at least 12 mo FU. Median 33 mo
(13–65). CT every 3–6 mo post-SBRT
Mass-like consolidation in 68% a
median of 5 mo (2–9) post-
SBRT, the size varied up to 12
mo post-SBRT but did not
increase after 12 mo except
when there was recurrence
11% of the mass-like lesions were
local recurrence on follow-up
(Continued)
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used have all been reported previously.21,22 Treatment was
delivered using 8 to 12 noncoplanar static beams and 6 MV
photons to a total dose of 60 Gy, calculated with a pencil
beam algorithm and prescribed at the 80% isodose line.
Fractionation was dependent on tumor size and its location: 3
fractions of 20 Gy were delivered to T1 tumors surrounded by
lung parenchyma; 5 fractions of 12 Gy to T2 tumors and T1
tumors in broad contact with the chest wall; and 8 fractions of
7.5 Gy to centrally located tumors and those close to the brachial
plexus. Routine follow-up involved outpatient assessments at 3,
6, and 12 months post-SBRT and thereafter every 6–12 months,
with a diagnostic CT scan of the thorax and upper abdomen
performed at each visit. Fluorodeoxyglucose positron emission
tomography-CT scanning is not performed routinely post-
SBRT. When intrathoracic disease recurrence is suspected, pa-
tients are discussed in a multidisciplinary tumor board consisting
of radiation oncologists, pulmonologists, nuclear medicine phy-
sicians, and radiologists, before recommendations are made for
a follow-up policy. Whether there is definite local recurrence is
often uncertain and a common approach involves repeat CT
imaging at a short interval (e.g., after 3 months) together with a
fluorodeoxyglucose positron emission tomography-CT scan and
invasive diagnostic procedures, if appropriate.
Scoring of Radiological Pneumonitis and
Fibrosis
Scoring of radiological changes was performed by three
radiation oncologists, who together had treated and followed
up more than 500 lung SBRT patients. Scoring was per-
formed in a meeting room with digital images of the baseline
and follow-up CT scans projected onto a large screen. Scores
were assigned by consensus.
Acute CT changes were defined as those occurring
within the first 6 months of treatment, using a scoring system
described previously8 (Figure 1A and Table 2). Briefly, the
five categories of acute findings defined were diffuse consol-
idation, patchy consolidation, diffuse ground-glass opacities
(GGOs), patchy GGO, or no evidence of increasing density.
The term “diffuse” was applied to abnormalities that were at
least 5 cm in maximum diameter and which contained more
than 50% abnormal lung; otherwise, the term “patchy” was
applied.
Late CT changes were defined as occurring 6 months
after treatment or later and classified into one of four cate-
gories10 (Figure 1B and Table 3): “modified conventional
pattern” of fibrosis (characterized by consolidation, volume
loss, and bronchiectasis  GGO), mass-like fibrosis (well-
circumscribed focal consolidation limited to the tumor region
but which is larger than the original tumor), “scar-like fibro-
sis” (a linear opacity in the tumor region with associated
volume loss), or “no evidence of increasing density” (regress-
ing mass at the location of the treated tumor or only normal
lung visible).
In addition, our system specified a subjective overall
impression of the severity of radiographic findings as follows:
“severe” (much more extensive than would usually be ex-
pected with SBRT); “moderate” (changes that are common),
“mild”/“minor” (slight changes only), or “none.”8
For patients undergoing treatment of more than one
lesion, CT changes associated with each lesion were scored
separately. Any scans in patients who were undergoing treat-
ment for acute infections, such as an infection, were not
scored.
Statistical Analysis
Associations between baseline factors and severity of
CT changes were calculated using Spearman’s correlation,
and the relationship between early and late severity scores
was assessed using McNemar’s test. Time to onset of first CT
changes was estimated using the Kaplan-Meier method, and
Cox regression analysis was used to determine whether base-
line factors (age, sex, COPD severity, comorbidity score,
smoking status, and tumor location) were related to time to
onset of first CT change. All statistical tests were two sided
with p  0.05 indicative of statistical significance, and all
statistical analyses were performed using the Statistical Pack-
age of Social Sciences (SPSS version 15.0, Chicago, IL).
RESULTS
Between 2003 and June 2008, a total of 387 patients
underwent SBRT for stage I NSCLC. Out of these, we
identified 147 patients who survived more than 2 years
post-SBRT and who did not develop local recurrence.
TABLE 1. (Continued)
Study Patients
Follow-Up (FU) Duration and Intended
Imaging Frequency
Lung Changes After Stereotactic
Body Radiotherapy (SBRT) Comments
Aoki et al.16 31 Patients had CT FU for median 14 mo
(2–31) post-SBRT. CT 2–3 monthly in
year 1 and 3–6 monthly afterward
Lung changes seen in all patients.
Early CT changes mainly
patchy consolidation (68%)
seen at 2–6 mo post-SBRT
(median 4). Late CT changes
mainly solid consolidation
(65%) at 6–15 mo (median 11)
No symptomatic lung
complications grade 2
Takeda
et al.17
20 (22 lesions) Monthly x-rays, CT 1 and 3 mo post-SBRT
and then 3 monthly. High-resolution CT
(HRCT) for tumors and pneumonitis.
Mean FU 17.6 mo after first HRCT
(4.5–51.6)
GGO and dense consolidation
most common initial findings in
18% at 3–6 mo and 73% at 3–8
mo, respectively
6–11 mo post-SBRT dense
consolidation shrank in 7/16
lesions becoming solid or linear
opacities, in 6/10 with 12 mo
FU these became fixed. Spatial
migration was also observed
Journal of Thoracic Oncology • Volume 6, Number 7, July 2011 Radiological Changes After Stereotactic Radiotherapy
Copyright © 2011 by the International Association for the Study of Lung Cancer 1223
TABLE 2. Scoring System for Classifying Acute Radiological
Changes After Stereotactic Body Radiotherapy (SBRT)8
Name Description
Diffuse
consolidation
Consolidation more than 5 cm in largest dimension.
The involved region contains more consolidation
than aerated lung
Patchy consolidation Consolidation less than 5 cm in largest dimension
and/or the involved region contains less
consolidation than aerated lung
Diffuse GGO More than 5 cm of GGO, (without consolidation).
The involved region contains more GGO than
normal lung
Patchy GGO Less than 5 cm of GGO, (without consolidation),
and/or the involved region contains less GGO
than normal lung
No evidence of
increased density
No new abnormalities. Includes patients with
tumors that are stable, regressing or resolved, or
fibrosis in the position of the original tumor that
is not larger than the original tumor
GGO, ground glass opacity.
TABLE 3. Scoring System for Classifying Late Radiological
Changes After Stereotactic Body Radiotherapy (SBRT)10
Name Description
Modified conventional
pattern
Consolidation, volume loss, and bronchiectasis
similar to, but usually less extensive than,
conventional radiation fibrosis. Larger than the
original tumor size. Occasionally with
associated GGO
Mass-like fibrosis Well-circumscribed focal consolidation limited to
area surrounding the tumor. The abnormality
must be larger than the original tumor
Scar-like fibrosis Linear opacity in the region of the tumor
associated with volume loss
No evidence of
increased density
No new abnormalities. Includes patients with
tumors that are stable, regressing or resolved,
or fibrosis in the position of the original tumor
that is not larger than the original tumor
GGO, ground glass opacity.
FIGURE 1. Classification of radiological changes after stereotactic body radiotherapy (SBRT). A, Acute radiological pneumoni-
tis within 6 months of treatment. One category (no increasing density) not shown. B, Late radiological fibrosis after more than
6 months from the time of treatment. One category (no increasing density) not shown. GGO, ground glass opacity.
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Sixty-one patients (Table 4) met all the inclusion criteria
for this evaluation, with the commonest reason for ineli-
gibility being CT scans performed in other centers and not
stored permanently on the VUmc picture archiving and
communication system.
The median age was 71 years, and the median duration
of CT follow-up was 2.5 years (range: 2–6.7 years). Thirty-
four patients had COPD that was scored as moderate (GOLD
III) or severe (GOLD IV), as per the GOLD criteria.23 The
median Charlson comorbidity score (nonage adjusted) was 4
(range 2–9), and 49 patients (80%) were medically inopera-
ble. The 61 patients were treated for a total of 68 lesions: six
patients were treated for two synchronous lesions, and one
patient was treated 2 years after the original course of SBRT
for a second primary tumor in a different lung region and was
followed up for a further 4 years. The pathological confirma-
tion rate was 34%, consistent with our previously reported
experience.21 A total of 325 CT scans were reviewed (me-
dian, 5 per patient, range 3–10), on which a total of 364 lesion
scores were assigned.
CT scans within 6 months of treatment were available
for 67 lesions (assessed in 70 scans). In 46% of cases, there
was no evidence of increasing density. In 36 (54%), there
were acute parenchymal changes. Acute patterns of CT
changes were as follows: 46% of lesions showed no evidence
of increasing density, 24% patchy consolidation, 16% diffuse
consolidation, 7% diffuse GGO, and 6% patchy GGO.
Late parenchymal CT changes were seen for nearly all
lesions (67/68; 99%) at some point during the follow-up
period. The incidence of CT changes at 6, 12, 24, and 36
months was 56%, 73%, 87%, and 99%, respectively. A total
of 294 late morphology scores were assigned, and the mod-
ified conventional pattern of fibrosis was most common
(71%), followed by scar-like fibrosis (11%), no evidence of
increasing density (11%), and mass-like fibrosis (7%). Most
lesions had a maximum severity score of 1 (mild; n  34;
50%) or 2 (moderate; n  32; 47%). Only one patient had
severe (score  3) changes after SBRT.
The severity of acute change was predictive of late
change severity: 55% of patients with moderate or severe
acute changes had moderate or severe late changes. In com-
parison, only 39% of patients with no/mild acute changes had
moderate or severe late changes (p  0.002). There were no
significant correlations between maximum severity score and
PTV size (p  0.14), fraction number (p  0.95), Charlson
score (p  0.32), smoking status (p  0.16), laterality (p 
0.51), or severity of COPD as measured by GOLD score (p
0.93). Time to onset of first CT change was faster in men than
in women (median: 26 weeks versus 47 weeks, p  0.015).
Other baseline factors, including age (p  0.16), smoking
status (p  0.87), PTV size (p  0.96), laterality (p  0.64),
central location (p  0.52), COPD severity (p  0.15), and
Charlson score (p  0.56) were not predictive of time to
onset of first CT change.
The cumulative incidence of CT changes is shown in
Figure 2. Although the actuarial median time to development
of first CT changes was 17 weeks, the first CT change
developed more than 1 year after treatment in 25% of lesions.
The time course of the morphology and severity of the lung
changes is shown in Figure 4. A continual evolution in
morphology was commonly observed: many lesions dem-
onstrated a modified conventional pattern after 1 year that
evolved thereafter into scar or mass-like patterns (Figure
3A). The severity of CT changes peaked between 1 and 2
years and then plateaued (Figure 3B). Although it appeared
to diminish beyond 4 years, this observation is based on a
small number of patients. Radiological parenchymal
changes continued to evolve long after SBRT, with 32
lesions (47%) showing either a change in morphology or
severity of the CT findings more than 2 years after treat-
ment (Figure 4).
FIGURE 2. Cumulative incidence plot of first computed to-
mography (CT) change after stereotactic body radiation
therapy (SBRT).
TABLE 4. Clinical and Treatment Characteristics for 61
Patients Treated with Stereotactic Lung Radiotherapy with At
Least 2 yr of Computed Tomography Follow-Up
Variable
Median (Range)
or Number (%)
Age (yr) 71 (48–85)
Gender
Female 32 (53)
Male 29 (47)
PTV volume (ml) 50 (15–122)
FEV1 (as percent of predicted) 64 (41–114)
Stage
T1 39 (64)
T2 22 (36)
Dose and fractionation
3  20 Gy 24 (39)
5  12 Gy 26 (43)
8  7.5 Gy 11 (18)
Duration of CT follow-up 2.5 yr (2–6.7 yr)
PTV, planning target volume; FEV1, forced expiratory volume in 1 second; CT,
computed tomography.
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DISCUSSION
To the best of our knowledge, this study reports the
longest duration of CT follow-up for assessment of normal
tissue changes in patients treated with lung SBRT (Table 1).
In addition, it systematically describes the frequency, timing,
longitudinal evolution, and severity of post-SBRT lung
changes. Although about half of patients developed acute CT
changes, we found that late CT changes occurred to some
extent in almost all patients. With respect to the timing of
these changes, it was noteworthy that in 25% of treated
lesions, the first CT changes become apparent more than 1
year after treatment. Importantly, CT changes were often
dynamic, with almost half of all cases showing signs of
evolution more than 2 years after radiotherapy. Significantly,
the proportion of mass-like changes seems to increase in
those patients with more than 2 years of imaging follow-up
and the severity of changes peaked at 1 to 2 years post-SBRT.
Although the severity of early change was predictive of late
changes—about half of the patients with moderate-severe
acute changes developed late changes of the same severity—
additional long-term clinical and radiographic follow-up is
still required to better characterize this relationship.24
To put the current data in context, 2 to 6 months after
lung SBRT Trovo et al.10 reported a 33% incidence of patchy
FIGURE 3. Temporal changes in
patterns and severity of computed
tomography (CT) changes after ste-
reotactic body radiation therapy
(SBRT). A, Morphological patterns of
CT changes by follow-up time pe-
riod. B, Severity of CT changes by
follow-up time period. GGO,
ground glass opacity. Number of
lesions scored during each time pe-
riod is shown at bottom (some le-
sions may have been scored more
than once during each period).
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consolidation/GGO and a 27% incidence of diffuse consoli-
dation, whereas we found 24% patchy and 16% diffuse
consolidation at 3 months. From 7 to 12 months and 13 to 18
months post-SBRT, they found 54% and 44% modified
conventional pattern, and 20% and 28% mass-like patterns
respectively. Whereas, in this study, beyond 6 months post-
SBRT, we found a modified conventional pattern in 71% and
mass-like fibrosis in 7%. Interobserver variation, sample size,
follow-up duration, patient characteristics, and SBRT treat-
ment technique may be among the factors that account for
these differences. Similar to Trovo et al.,10 we found no
relationship between radiographic changes and the PTV
size. However, in contrast with the conclusions of Linda et
al.25 in a recent review, we have seen that morphological
change is commonplace beyond 2 years after SBRT. The
dominant acute (patchy consolidation) and late (solid/
discrete consolidation) findings of Aoki et al.16 are con-
sistent with our own observations. Guckenberger et al.9
report similar findings but use the terms dense consolida-
tion, spotted streaky consolidation, and retraction to de-
scribe the late changes. Our finding that late consolidation
can subsequently evolve into a mass or scar-like pattern is
consistent with the report of Takeda et al.17
The fact that multiple series report similar morphologic
time trends with conventionally delivered SBRT is perhaps
not surprising given that they are all describing pneumonitis
and subsequent fibrosis. Nevertheless, the differences in de-
scriptive terminology and scoring metrics highlight that it
would be desirable to develop a standardized and validated
scoring system that could be consistently applied.24 This is
especially important for clinical trials. Although the qualita-
tive method of reporting changes used in this article is
currently most relevant to everyday clinical practice, more
objective methods for evaluating lung changes post-SBRT
are required. A quantitative methodology that uses deform-
able image registration to correlate lung density changes with
radiation dose distributions is currently undergoing evalua-
tion for this purpose.26,27
Although we consider our methodology to be at least as
robust as previously reported studies (Table 1), there are
some potential limitations. First, it is clear that the follow-up
imaging interval will contribute substantially to the estimated
timeline for normal tissue responses. In this instance, scans
were performed at 3, 6, and 12 months after SBRT, and
thereafter every 6–12 months, which means that there could
be an uncertainty of up to several months in when normal
tissue changes actually occurred. Inevitably, the number of
patients at risk declines with time, and so it is feasible that the
incidence and the characteristics of morphological change
could also alter with longer follow-up and a larger number of
patient observations, especially at later time points. For ex-
ample, observations in this study beyond 2.5 to 3 years are
based on a relatively small number of patients. The frequency
of changes could be further influenced by the test-retest
variability of the scoring systems, which was not specifically
evaluated in this report. Although somewhat subjective, the
scoring system’s descriptive qualities do mean that it could be
used in the clinical setting, and the addition of a severity
score provides an extra dimension and discriminator over
previous reports.
Our report was not intended to focus on the relationship
of radiological changes to potential patho-etiological factors,
symptoms, or medication. Nor has it considered possible
dosimetric risk factors for clinical lung toxicity after SBRT or
the effect on lung function.28 In addition, this study does not
focus on the identification of local recurrence. It is also
important to note that the findings in this study relate to
patients treated with multiple noncoplanar conformal beams
and 6 MV photons. Volumetric modulated arc therapy is now
the standard technique for lung SBRT at our center,29 and
FIGURE 4. These two examples illustrate the dynamic nature of computed tomography (CT) changes after lung stereotactic
body radiation therapy (SBRT) 3  20 Gy. In the top panel, the treatment CT is on the left. From left to right: “no increase in
density” on CT at 6 and 13 months and then a “modified conventional” pattern first appears at 25 months and is still
present at 37 months. In the case illustrated in the bottom panel, the treatment CT is again on the left. From left to right:
no increase in density at 7 months changing to modified conventional pattern at 13 months, evolving to “mass-like”
change on CT at 24 months post-SBRT and then reverting again to modified conventional at 38 months.
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changes in the pattern of late radiological changes cannot be
ruled out as larger volumes of lung tissue may be exposed to
lower doses of radiation in these patients. Finally, it follows
that distinguishing lung changes from local recurrence is of
great importance, not least of all because there are salvage
options for selected patients.30,31 Importantly, in two recent
articles describing salvage surgery, the authors reported that
the local recurrences were associated with rapid enlarge-
ment within a relatively short period after SBRT. Contin-
ued radiological follow-up of parenchymal lung change is,
therefore, necessary, with multidisciplinary review, in-
creased imaging frequency, metabolic studies, and inva-
sive evaluation as appropriate.
In conclusion, with increasing numbers of patients
receiving lung SBRT, it is important that their medical team
is aware of specific characteristics of this treatment. This
preliminary study of post-SBRT fibrotic changes has demon-
strated that long-term CT changes and continued radiographic
evolution are common more than 2 years after SBRT. Addi-
tional work is now needed to improve the early detection of
local progression and to better understand the pathogenesis of
lung changes post-SBRT and their long-term physiological
and functional effects.
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